enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of “Hold” from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has been given an average recommendation of “Hold” by the fourteen analysts that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $11.0455.

A number of equities research analysts have issued reports on ENGN shares. Wall Street Zen downgraded shares of enGene from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Leerink Partners cut shares of enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price target on the stock. in a report on Friday, May 8th. WBB Securities initiated coverage on shares of enGene in a research note on Monday, April 13th. They issued a “buy” rating and a $21.50 price target on the stock. Citizens Jmp lowered enGene from an “outperform” rating to a “market perform” rating in a report on Friday, May 8th. Finally, Piper Sandler cut enGene from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $7.00 to $4.00 in a research report on Friday, May 8th.

Institutional Investors Weigh In On enGene

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Privium Fund Management B.V. acquired a new stake in enGene in the fourth quarter valued at approximately $3,179,000. Braidwell LP acquired a new position in shares of enGene during the 3rd quarter worth $15,479,000. Perceptive Advisors LLC increased its stake in shares of enGene by 179.8% during the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock worth $52,998,000 after purchasing an additional 3,771,840 shares during the last quarter. Omega Fund Management LLC raised its holdings in shares of enGene by 66.5% during the 4th quarter. Omega Fund Management LLC now owns 876,357 shares of the company’s stock valued at $7,914,000 after purchasing an additional 350,000 shares in the last quarter. Finally, Eventide Asset Management LLC bought a new position in shares of enGene during the 4th quarter valued at $8,578,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Price Performance

NASDAQ ENGN opened at $1.78 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 12.57 and a quick ratio of 12.57. The firm has a market capitalization of $119.24 million, a price-to-earnings ratio of -0.82 and a beta of -0.28. The company has a 50 day simple moving average of $2.65 and a 200-day simple moving average of $6.57. enGene has a 52-week low of $1.40 and a 52-week high of $12.25.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Monday, June 15th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.91. During the same quarter in the previous year, the company earned $0.51 EPS. Equities research analysts predict that enGene will post -1.84 earnings per share for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.